The binding region contained highly active chromatin, as determined by high levels of histone 3 trimethylation at lysine 4 (H3K4me3) and H3 acetylation, as well as RNA polymerase II occupancy.
The first poster demonstrates proof-of-concept data that Aqtual's therapy selection test can predict treatment response in patients with RA. The second poster provides an interim analysis from ...